Anticancer properties of new flavonoid lensoside Aβ in combination with temozolomide in an in vitro model of human glioma cells.

Malignant gliomas like astrocytoma IDH mutant and glioblastoma IDH wild type, particularly anaplastic astrocytoma and glioblastoma multiforme, represent significant therapeutic challenges due to their aggressive behavior and resistance to treatment. This study investigates the effect of simultaneous effects of the new flavonoid lensoside Aβ in combination with temozolomide in human glioma cell lines (T98G, MOGGCCM, LN-18, LN229, and SW1783). Emphasis was placed on the modulation of the PI3K/AKT/mTOR and RAF/MEK/ERK pathways, which are integral to cancer progression. Migration inhibition was evaluated through in vitro wound assays and scanning electron microscopy, whereas apoptosis and cell death were quantified via flow cytometry and fluorescence microscopy. The results revealed that lensoside Aβ enhances temozolomide's efficacy, particularly in LN229 cells, while highlighting differential drug responses in LN-18 cells. These findings underscore the potential of combining lensoside Aβ with standard chemotherapeutics to mitigate glioma invasiveness and resistance, thereby opening avenues for molecular-targeted therapy strategies.